Lin Yan, Kong De-Xia, Zhang You-Ni
Health Management Center, Department of General Practice, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, China.
Department of Laboratory Medicine, Tiantai People's Hospital, Taizhou, China.
Front Oncol. 2022 Apr 8;12:852194. doi: 10.3389/fonc.2022.852194. eCollection 2022.
Colorectal cancer (CRC) is the second most common malignancy globally, and many people with CRC suffer the fate of death. Due to the importance of CRC and its negative impact on communities, treatment strategies to control it or increase patient survival are being studied. Traditional therapies, including surgery and chemotherapy, have treated CRC patients. However, with the advancement of science, we are witnessing the emergence of novel therapeutic approaches such as immunotherapy for CRC treatment, which have had relatively satisfactory clinical outcomes. Evidence shows that gastrointestinal (GI) microbiota, including various bacterial species, viruses, and fungi, can affect various biological events, regulate the immune system, and even treat diseases like human malignancies. CRC has recently shown that the gut microorganism pattern can alter both antitumor and pro-tumor responses, as well as cancer immunotherapy. Of course, this is also true of traditional therapies because it has been revealed that gut microbiota can also reduce the side effects of chemotherapy. Therefore, this review summarized the effects of gut microbiota on CRC immunotherapy.
结直肠癌（CRC）是全球第二常见的恶性肿瘤，许多CRC患者面临死亡的命运。由于CRC的重要性及其对社会的负面影响，正在研究控制它或提高患者生存率的治疗策略。包括手术和化疗在内的传统疗法已用于治疗CRC患者。然而，随着科学的进步，我们目睹了诸如用于CRC治疗的免疫疗法等新型治疗方法的出现，这些方法已取得了相对令人满意的临床结果。有证据表明，胃肠道（GI）微生物群，包括各种细菌、病毒和真菌，可影响各种生物学事件、调节免疫系统，甚至治疗人类恶性肿瘤等疾病。最近有研究表明，CRC患者的肠道微生物模式可改变抗肿瘤和促肿瘤反应以及癌症免疫治疗效果。当然，传统疗法也是如此，因为有研究表明肠道微生物群还可降低化疗的副作用。因此，本综述总结了肠道微生物群对CRC免疫治疗的影响。
